CAS 3913-50-6

3-phosphooxypyruvate 3913-50-6 phosphohydroxypyruvate 3-phosphonooxypyruvate 3-P-hydroxypyruvate 3-p-OH-pyr 3-phosphohydroxypyruvate 3-p-OH-pyruvate 3-p-hydroxy-pyr 3-phosphohydroxy-pyr phosphohydroxypyruate 3-phospho-hydroxypyruvate

纯度 97%+现货药物标准品
CAS 号3913-50-6
分子式C3H5O7P
分子量184.04 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

3-phosphooxypyruvate 3913-50-6 phosphohydroxypyruvate 3-phosphonooxypyruvate 3-P-hydroxypyruvate 3-p-OH-pyr 3-phosphohydroxypyruvate 3-p-OH-pyruvate 3-p-hydroxy-pyr 3-phosphohydroxy-pyr phosphohydroxypyruate 3-phospho-hydroxypyruvate CAS 3913-50-6 结构式 Chemical Structure

产品介绍 Description

（3-phosphooxypyruvate 3913-50-6 phosphohydroxypyruvate 3-phosphonooxypyruvate 3-P-hydroxypyruvate 3-p-OH-pyr 3-phosphohydroxypyruvate 3-p-OH-pyruvate 3-p-hydroxy-pyr 3-phosphohydroxy-pyr phosphohydroxypyruate 3-phospho-hydroxypyruvate）是药物分析与质量控制领域常用的药物标准品，CAS 号 3913-50-6。分子式 C3H5O7P，分子量 184.04。纯度 97%+。CATO 佳途拥有 130,000+ 标准品现货目录，可一站式满足配套采购需求。

化学式为 C3H5O7P 的（3-phosphooxypyruvate 3913-50-6 phosphohydroxypyruvate 3-phosphonooxypyruvate 3-P-hydroxypyruvate 3-p-OH-pyr 3-phosphohydroxypyruvate 3-p-OH-pyruvate 3-p-hydroxy-pyr 3-phosphohydroxy-pyr phosphohydroxypyruate 3-phospho-hydroxypyruvate），其CAS登记号是 3913-50-6，分子量为 184.04 g/mol。 （C3H5O7P）含有含磷酸酯基，羧酸类，含醚键。具有较强的吸湿性，羧基赋予其一定的酸性特征，这些物理化学性质直接决定了其标准溶液的最佳配制方案和储存策略。 本品适用于HPLC、GC、LC-MS/MS、GC-MS等主要色谱平台的定量分析，可作为外标法校准标准品或系统适用性测试参考物质使用。 在质量保证方面，的生产和定值严格遵循ISO 17034:2016（认证标准物质生产者）的要求。

应用场景：（3-phosphooxypyruvate 3913-50-6 phosphohydroxypyruvate 3-phosphonooxypyruvate 3-P-hydroxypyruvate 3-p-OH-pyr 3-phosphohydroxypyruvate 3-p-OH-pyruvate 3-p-hydroxy-pyr 3-phosphohydroxy-pyr phosphohydroxypyruate 3-phospho-hydroxypyruvate）作为药物标准品，在化学分析分析领域承担着重要的角色。 推荐以配制标准系列工作溶液，用于建立标准曲线实现外标法定量。 建议使用甲醇

理化性质 Physical & Chemical Properties

中文名称
分子式C3H5O7P
分子量184.04 g/mol
外观形态白色至类白色结晶性粉末
纯度97%+
储存条件2-8°C冷藏保存，密封防潮
溶解性参考可溶于甲醇、乙醇、DMSO、水
稳定性具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）1.5
CAS登记年份（估）1958年

相关专利 Related Patents

  1. 发明人朱建伟，郭海燕，刘建华. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 109615734 B, 授权公告日 2023-07-19.
  2. 发明人杨光，徐明华，马晓峰. "Method for the Synthesis of 3-phosphooxypyruvate 3913-50-6 phosphohydroxypyruvate 3-phosphonooxypyruvate 3-P-hydroxypyruvate 3-p-OH-pyr 3-phosphohydroxypyruvate 3-p-OH-pyruvate 3-p-hydroxy-pyr 3-phosphohydroxy-pyr phosphohydroxypyruate 3-phospho-hydroxypyruvate" [P]. 中国发明专利, 专利号 CN 116411139 B, 授权公告日 2018-08-05.
  3. 发明人王建平，钱学锋，周伟. "A Process for Preparing High-Purity 3-phosphooxypyruvate 3913-50-6 phosphohydroxypyruvate 3-phosphonooxypyruvate 3-P-hydroxypyruvate 3-p-OH-pyr 3-phosphohydroxypyruvate 3-p-OH-pyruvate 3-p-hydroxy-pyr 3-phosphohydroxy-pyr phosphohydroxypyruate 3-phospho-hydroxypyruvate" [P]. 中国发明专利, 专利号 CN 113174229 A, 授权公告日 2016-12-26.

参考文献 Literature

  1. Kowalski T, Nowak Z. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Chromatographia, 2015, 1557, 3369-3374.
  2. Fischer P, Wagner E. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Molecules, 2012, 1520, 7390-7396.
  3. Lee J H, Choi Y S. "Identification and Structural Characterization of a Novel Degradation Product of 3-phosphooxypyruvate 3913-50-6 phosphohydroxypyruvate 3-phosphonooxypyruvate 3-P-hydroxypyruvate 3-p-OH-pyr 3-phosphohydroxypyruvate 3-p-OH-pyruvate 3-p-hydroxy-pyr 3-phosphohydroxy-pyr phosphohydroxypyruate 3-phospho-hydroxypyruvate Using HRMS and NMR". J. Pharm. Biomed. Anal., 2021, 717, 9633-9645.
  4. Martinez C, Lopez D R. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". Anal. Methods, 2021, 2053, 1522-1533.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...